歡迎關注生物醫學中文摘要!關注後,回復受體即可下載這邊文章!
我們開發了治療神經變性的臨床前療法,其選擇性靶向雄激素受體的AF-2結構域,同時抑制了該受體的其他功能。
【題目】雄激素受體AF2結構域的選擇性調節可挽救脊髓延髓肌萎縮症的變性
【摘要】脊髓延髓肌萎縮症(SBMA)是由雄激素受體(AR)功能毒性增加引起的運動神經元疾病。以前,我們發現通與過AR的(AF2)結構域的共調節物結合對於發病機制是必不可少的,這表明AF2可能是選擇性調節毒性AR活性的潛在藥物靶標。我們篩選了之前鑑定的AF2調節劑,它們能夠在SBMA的果蠅模型中逆轉毒性。 我們確定了兩種化合物託芬那酸(TA)和1- [2-(4-甲基苯氧基)乙基]-2 - [(2-苯氧基乙基)硫烷基] -1H-苯並咪唑(MEPB),作為逆轉致命性、運動、功能和SBMA蒼蠅神經肌肉接頭缺陷的最佳候選者。小鼠中的藥代動力學分析顯示與肌肉,大腦和脊髓中的TA相比,MEP型小鼠的更有利的生物利用度和組織保留。 在SBMA新型小鼠模型的臨床前試驗中,MEPB治療從體重減輕、旋轉桿菌活性和握力方面產生了劑量依賴性的逆轉。此外,MEPB改善了神經元丟失、神經原性萎縮和睪丸萎縮,驗證了AF2調節是一種保留雄激素有效的SBMA療法。
【report】 Apreclinical therapy to treat neurodegeneration is developed that selectivelytargets the AF-2 domain of the androgen receptor while sparing other functionsof this receptor.
【title】Selectivemodulation of the androgen receptor AF2 domain rescues degeneration in spinalbulbar muscular atrophy
【authors】Nisha M Badders, Ane Korff,Helen C Miranda, Pradeep K Vuppala, Rebecca B Smith, Brett J Winborn,Emmanuelle R Quemin, Bryce L Sopher, Jennifer Dearman, James Messing, Nam ChulKim, Jennifer Moore, Brian D Freibaum, Anderson P Kanagaraj, Baochang Fan,Heather Tillman, Ping-Chung Chen, Yingzhe Wang, Burgess B Freeman III, YimeiLi, Hong Joo Kim, Albert R La Spada & J Paul Taylor
【abstract】Spinal bulbar muscular atrophy (SBMA) is a motorneuron disease caused by toxic gain of function of the androgen receptor (AR).Previously, we found that co-regulator binding through the activation function-2(AF2) domain of AR is essential for pathogenesis, suggesting that AF2 may be apotential drug target for selective modulation of toxic AR activity. Wescreened previously identified AF2 modulators for their ability to rescuetoxicity in a Drosophila model of SBMA. We identified two compounds,tolfenamic acid (TA) and1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole(MEPB), as top candidates for rescuing lethality, locomotor function andneuromuscular junction defects in SBMA flies. Pharmacokinetic analyses in micerevealed a more favorable bioavailability and tissue retention of MEPB comparedwith TA in muscle, brain and spinal cord. In a preclinical trial in a new mousemodel of SBMA, MEPB treatmentyielded a dose-dependent rescue from loss of body weight, rotarod activity andgrip strength. In addition, MEPB ameliorated neuronal loss, neurogenic atrophyand testicular atrophy, validating AF2 modulation as a potent androgen-sparingstrategy for SBMA therapy.